Menarini Asia-Pacific, a member of the Menarini Group, has been granted the exclusive rights to market and sell Moberg Pharma’s Kerasal Nail on the Chinese market.
Kerasal Nail is a non-prescription product for the treatment of discoloured and deformed nails resulting from fungal infection or psoriasis. Since the launch in 2011 it has been launched in more than 25 countries.
The extended distribution agreement builds on an existing collaboration between Moberg Pharma and Menarini Asia-Pacific, which resulted in a successful launch of the product in Italy. In Asia-Pacific, Menarini is a leading regional biopharmaceutical company. It has over 3500 employees in 13 markets and a strong track record in launching and promoting Consumer Health brands. The global sales of the Menarini Group exceed 3 billion Euros.
“We are excited by the opportunity to enter the huge and rapidly expanding Chinese market. There are challenges related to China’s sheer size, business complexity, regulatory environment and infrastructure. With its profound understanding of local market conditions, Menarini Asia-Pacific is an ideal partner in this region. The extended agreement enables us to build on our successful commercial track record together with Menarini”, said Peter Wolpert, CEO of Moberg Pharma AB in a press release.